Restructuring and other costs in the first quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

In the first quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the Company’s workforce.

Restructuring and other costs in the first quarter of fiscal year 2025 primarily consisted of charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows:


	Three Months Ended
	April 5, 2026		March 30, 2025
	(In thousands)
Life Sciences	$	3,229	$	2,528
Diagnostics	7,554		135
Corporate	(108)		576
	$	10,675	$	3,239

The following table summarizes the changes in the Company’s accrued restructuring balance for the first quarter of fiscal year 2026. Other amounts reported as restructuring and other costs during the three months ended April 5, 2026 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in accrued expenses and other current liabilities in the consolidated balance sheets.


	(In thousands)








Balance at December 28, 2025	$	17,793
Net restructuring charges incurred in 2026 (a)	7,746
Payments	(11,555)

Balance at April 5, 2026	$	13,984

(a) Excludes $2.9 million of charges, principally $1.2 million of lease abandonment charges and $0.4 million of acceleration of depreciation of fixed assets and other charges in the Diagnostics segment and $1.3 million of lease abandonment charges in the Life Sciences segment.